Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $7.60 price target on the stock, up previously from $7.00.
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023) [Yahoo! Finance]
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.